Understanding the Evidence for Medical Cannabinoids for the Treatment of Chronic Pain
Keywords:Chronic pain, Medical cannabinoids, Opioids, Pain management, Treatment, THC, CBD, Analgesic drugs
This paper is an examination of the existing literature on the use of medical cannabinoids for the treatment of adults with chronic pain (CP). The use of medical cannabinoids in the treatment of CP has been a controversial topic due to societal associations with the recreational use of cannabis and the lack of information as to their analgesic effects. This paper analyzes trends in how medical cannabinoids perform as an analgesic treatment for adults with CP, especially in comparison to opioids. Additionally, this paper explores any secondary effects participants may experience as a result of treatment with medical cannabinoids. It will be shown that, while medical cannabinoids have the potential to reduce pain in those suffering from CP, there are numerous factors that must be considered before they become an acceptable treatment option. In addition, there is evidence that the analgesic effects of medical cannabinoids may be primarily due to their intoxicating effect rather than their interaction with neural pain pathways. This review of existing literature acts to guide future research on the use of medical cannabinoids for the treatment of CP.
References or Bibliography
Lichtman AH, Lux EA, McQuade R, et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management. 2018;55(2):179-188. doi:10.1016/j.jpainsymman.2017.09.001.
Weizman L, Dayan L, Brill S, et al. Cannabis analgesia in chronic neuropathic pain is associated with altered brain connectivity. Neurology. 2018;91(14):1285-1294. doi:10.1212/WNL.0000000000006293.
Poli P, Crestani F, Salvadori C, Valenti I, Sannino C. Medical cannabis in patients with chronic pain: effect on pain-relief, pain disability, and psychological aspects. A productive non randomized single arm clinical trial. Societa Editrice Universo. 2018;169(3):102-107. doi:10.7417/T.2018.2062.
Campbell G, Stockings E, Nielsen S. Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain. European Archives of Psychiatry and Clinical Neuroscience. 2019;269(1):135-144. doi:10.1007/s00406-018-0960-9.
van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. PAIN. 2019;160(4):860-869. doi:10.1097/j.pain.0000000000001464.
Galea S. Chronic pain and the health of populations. Boston University School of Public Health. https://www.bu.edu/sph/2017/09/24/chronic-pain-and-the-health-of-populations. Published September 24, 2017. Accessed October 28, 2019.
Hegmann KT, Feinberg SD, Aronoff GM, et al. Chronic pain guideline. American College of Occupational and Environmental Medicine. https://www.dir.ca.gov/dwc/MTUS/ACOEM_Guidelines/Chronic-Pain-Guideline.pdf. Published May 15, 2017. Accessed October 28, 2019.
Ware MA, Wang T, Shapiro S, Collet JP. Cannabis for the management of pain: assessment of safety study (COMPASS). The Journal of Pain. 2015;16(12):1233-1242. doi:10.1016/j.jpain.2015.07.014.
Sohler NL, Starrels J, Khalid L, et al. Cannabis use is associated with lower odds of prescription opioid analgesic use among HIV-infected individuals with chronic pain. Substance Use & Misuse. 2018;53(10):1602-1607. doi:10.1080/10826084.2017.1416408.
de Vries M, van Rijckevorsel DCM, Vissers KCP, Wilder-Smith OHG, van Goor H. Tetrahydrocannabinol does not reduce pain in patients with chronic abdominal pain in a phase 2 placebo-controlled study. Clinical Gastroenterology and Hepatology. 2017;15(7):1079-1086. doi:10.1016/j.cgh.2016.09.147.
Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M. Impact of co-administration of oxycodone and smoke cannabis on analgesia and abuse liability. Neuropsychopharmacology. 2018;43(10):2046-2055. doi:10.1038/s41386-018-0011-2.
Schimrigk S, Marziniak M, Neubauer C, Kugler EM, Werner G, Abramov-Sommariva D. Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology. 2017;78(5-6):320-329. doi:10.1159/000481089.
Wilsey B, Marcotte TD, Deutsch R, Zhao H, Prasad H, Phan A. An exploratory human laboratory experiment evaluating vaporized cannabis in the treatment of neuropathic pain from spinal cord injury and disease. The Journal of Pain. 2016;17(9):982-1000. doi:10.1016/j.jpain.2016.05.010.
Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of inhaled cannabis on painful diabetic neuropathy. The Journal of Pain. 2015;16(7):616-627. doi:10.1016/j.jpain.2015.03.008.
Babalonis S, Haney M, Malcolm RJ, et al. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug and Alcohol Dependence. 2017;172:9-13. doi:10.1016/j.drugalcdep.2016.11.030.
How to Cite
Copyright (c) 2021 Sophia Rougraff
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.